Kiniksa Pharmaceuticals Ltd (KNSA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
KNSA
Kiniksa Pharmaceuticals Ltd
$48.42
-1.65%
HEALTHCARE · Cap: $3.99B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 597440% more annual revenue ($4.51T vs $754.04M). KNSA leads profitability with a 9.7% profit margin vs 4.3%. TAK trades at a lower P/E of 42.5x. TAK earns a higher WallStSmart Score of 57/100 (C).
KNSA
Buy53
out of 100
Grade: C-
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.3%
Fair Value
$197.77
Current Price
$48.42
$149.35 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Earnings expanding 145.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 57.0x leaves little room for execution misses.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
KNSA carries more volatility with a beta of 0.12 — expect wider price swings.
KNSA is growing revenue faster at 55.5% — sustainability is the question.
KNSA generates stronger free cash flow (50M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 53/100). KNSA offers better value entry with a 77.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is a pioneering biopharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapies. Its lead candidate, KPL-404, is a monoclonal antibody specifically engineered to modulate immune responses, showcasing its potential in treating various autoimmune disorders. With a robust clinical pipeline and strategic partnerships bolstering its research and development efforts, Kiniksa is positioned for sustained growth in the competitive biopharmaceutical landscape. The company's steadfast commitment to innovation and reimagining treatment paradigms presents a compelling opportunity for institutional investors seeking impactful investments in transformative healthcare solutions.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?